Ingevity (NGVT) recently adjusted its full-year outlook, citing ongoing pressure from tariffs and competition in its Advanced Polymer Technologies segment. The update was paired with mixed earnings and progress from recent portfolio changes.

See our latest analysis for Ingevity.

Ingevity’s recent announcements, highlighting ongoing headwinds in Advanced Polymer Technologies and a strategic shift towards higher-margin segments, have clearly influenced sentiment. The stock’s almost 38% share price return year-to-date suggests recovering momentum, though its one-year total shareholder return of 15% still trails its longer-term averages.

If you’re curious to see which other specialty materials companies are capitalizing on changing market dynamics, you might enjoy the chance to discover fast growing stocks with high insider ownership.

With analysts pointing to both operational recovery and lingering risks, the real question is whether Ingevity’s recent share price gains still leave room for upside or if the stock has fully priced in the road ahead.

Ingevity’s most closely watched narrative places its fair value at $65.25, compared to a recent close of $54.46. This significant gap signals that some believe the market is still not fully appreciating a turnaround, given the updated outlook and progress on portfolio transformation.

Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile. This would enable greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.

Read the complete narrative.

Curious about the real math behind this valuation gap? The forecast hinges on a profit shift and a future multiple that would surprise most in this industry. Want the details that could move the stock? Crack open the full narrative and see what’s driving these bullish projections.

Result: Fair Value of $65.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent weakness in Advanced Polymer Technologies and ongoing tariff uncertainty remain key risks. These factors could quickly challenge this optimistic outlook.

Find out about the key risks to this Ingevity narrative.

While the narrative and DCF suggest Ingevity is undervalued, its price-to-sales ratio tells a different story. Trading at 1.5x, Ingevity is pricier than both the industry average (1.1x) and the fair ratio of 1.3x. This premium hints at valuation risk rather than opportunity. Might investors be overpaying for future growth?

See what the numbers say about this price — find out in our valuation breakdown.

If you’re inclined to dig into the details and form your own outlook, it’s simple to build a personalized story in just a few minutes. Do it your way.

A great starting point for your Ingevity research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Smart investing is all about staying one step ahead. Don’t miss out on fresh opportunities that could take your portfolio further. See what’s setting the pace in these standout spaces:

Unlock potential for stable income streams by tapping into 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 20 dividend stocks with yields > 3% that maintain impressive yields and strong financial foundations.

Capture upside in the fast-evolving world of medicine with these 33 healthcare AI stocks, featuring companies revolutionizing patient outcomes using artificial intelligence.

Seize rare value opportunities by tracking these 846 undervalued stocks based on cash flows where market prices lag behind actual fundamentals. Future gains could be the reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NGVT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com